Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV E7 degrader
- Development stage
- Preclinical
- Lead developer
- Valdospan
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MolGenie is developing small molecule targeted protein degraders that target the HPV E7 oncoprotein for the treatment of HPV-related cancers, including cervical and head and neck cancers. These compounds utilize MolGenie's proprietary PromptDegrader™ technology, which specifically targets the Intrinsically Disordered Regions (IDRs) of the E7 protein to induce its degradation. Unlike traditional PROTACs, this technology does not rely on a single E3 ligase. The development of these degraders involved ultralarge-scale database screening of multi-component reaction (MCR) products and 3D docking experiments with an elaborated model of the E7 protein. Valdospan GmbH is slated to lead the further development of this program.
- Other names
- E7 protein inhibitorE-7 protein inhibitorE 7 protein inhibitorE7 protein degraderE-7 protein degraderE 7 protein degraderPromptDegrader E7
02
Targets
E7 (Papillomavirus E6/E7 oncoproteins)
Beyond the preview
Go deeper on HPV E7 degrader.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV E7 degrader.